Wild-Type A Influenza Virus A/Belgium/4217/2015 (H3N2)

A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled, Single Dose and Single-Dose Challenge Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intranasal EV25 in Healthy Volunteers and in Influenza Challenge Participants

A Phase 2a Randomized, Double-blind, Placebo-controlled Trial with Open-label Dose-finding Cohorts to Evaluate the Efficacy and Safety of CR9114 Monoclonal Antibody Administered as Intranasal Doses in Healthy Adult Participants who are Challenged with a Live, Wild-type Influenza Type A Virus (A/Belgium/4217/2015 H3N2)